Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
BioSpace
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
pharminent
August 20, 2026 (Last updated: August 26, 2026)
BioSpace
Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
